PRINCETON, N.J., Jan. 14, 2020 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today...
FDA clears IND application for AVR-RD-02 First patient consented in GAU-201, a global Phase 1/2 trial of AVR-RD-02 in Gaucher disease type 1 All global clinical sites will be supported by proprietary plato™ platform January 14, 2020 07:00 AM Eastern Standard Time...
Mechelen, Belgium; 13 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) has completed recruitment for the PINTA Phase 2 clinical trial with oral GPR84 inhibitor GLPG1205. PINTA is a randomized, double-blind, placebo-controlled Phase 2 trial...
YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) — ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the...
LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with advanced solid tumors. This follows the recent...
Email
Text